The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkab… Más…
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles. TOC:From the Contents.- Protein Kinase Inhibitors for the Treatment of Disease; the Promise and the Problems.- Part 1: General Aspects of PKs Inhibition.- New Design Strategies for Ligands that Target Protein Kinase Mediated Protein-Protein Interactions.- Part 2: Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones, a Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase -3. Pharmacological Potential of p38 MAPK Inhibitors. Inhibitors of PKA and Related Protein Kinases. Inhibitors of Protein Kinase CK2: Structural Aspects. Aminoglycoside Kinases and Antibiotic Resistance.- Part 3: Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets. Structure-Based Design of PTP Inhibitors. Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target. Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Part 4: Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression Using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus. Targeted Therapy with Imatinib: An Exception or a Rule? Clinical Aspects of Imantinib Therapy. Isoquinolinesulfonamide, a Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy. Discovery and Development of Iressa - The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. eBook Springer PDF, Springer, 30.03.2006, Springer, 2006<
Thalia.de
Nr. 24485740. Gastos de envío:, Sofort per Download lieferbar, DE. (EUR 0.00) Details...
(*) Libro agotado significa que este título no está disponible por el momento en alguna de las plataformas asociadas que buscamos.
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkab… Más…
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles. TOC:From the Contents.- Protein Kinase Inhibitors for the Treatment of Disease; the Promise and the Problems.- Part 1: General Aspects of PKs Inhibition.- New Design Strategies for Ligands that Target Protein Kinase Mediated Protein-Protein Interactions.- Part 2: Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones, a Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase -3. Pharmacological Potential of p38 MAPK Inhibitors. Inhibitors of PKA and Related Protein Kinases. Inhibitors of Protein Kinase CK2: Structural Aspects. Aminoglycoside Kinases and Antibiotic Resistance.- Part 3: Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets. Structure-Based Design of PTP Inhibitors. Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target. Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Part 4: Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression Using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus. Targeted Therapy with Imatinib: An Exception or a Rule? Clinical Aspects of Imantinib Therapy. Isoquinolinesulfonamide, a Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy. Discovery and Development of Iressa - The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. eBook Springer PDF, Springer, 30.03.2006, Springer, 2006<
Thalia.de
Nr. 24485740. Gastos de envío:, Sofort per Download lieferbar, DE. (EUR 0.00) Details...
(*) Libro agotado significa que este título no está disponible por el momento en alguna de las plataformas asociadas que buscamos.
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkab… Más…
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles. TOC:From the Contents.- Protein Kinase Inhibitors for the Treatment of Disease; the Promise and the Problems.- Part 1: General Aspects of PKs Inhibition.- New Design Strategies for Ligands that Target Protein Kinase Mediated Protein-Protein Interactions.- Part 2: Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones, a Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase -3. Pharmacological Potential of p38 MAPK Inhibitors. Inhibitors of PKA and Related Protein Kinases. Inhibitors of Protein Kinase CK2: Structural Aspects. Aminoglycoside Kinases and Antibiotic Resistance.- Part 3: Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets. Structure-Based Design of PTP Inhibitors. Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target. Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Part 4: Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression Using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus. Targeted Therapy with Imatinib: An Exception or a Rule? Clinical Aspects of Imantinib Therapy. Isoquinolinesulfonamide, a Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy. Discovery and Development of Iressa - The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. eBook Springer 30.03.2006, Springer, Springer<
Orellfuessli.ch
Nr. 24485740. Gastos de envío:, Sofort per Download lieferbar, zzgl. Versandkosten. (EUR 16.85) Details...
(*) Libro agotado significa que este título no está disponible por el momento en alguna de las plataformas asociadas que buscamos.
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkab… Más…
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles. TOC:From the Contents.- Protein Kinase Inhibitors for the Treatment of Disease; the Promise and the Problems.- Part 1: General Aspects of PKs Inhibition.- New Design Strategies for Ligands that Target Protein Kinase Mediated Protein-Protein Interactions.- Part 2: Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones, a Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase -3. Pharmacological Potential of p38 MAPK Inhibitors. Inhibitors of PKA and Related Protein Kinases. Inhibitors of Protein Kinase CK2: Structural Aspects. Aminoglycoside Kinases and Antibiotic Resistance.- Part 3: Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets. Structure-Based Design of PTP Inhibitors. Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target. Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Part 4: Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression Using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus. Targeted Therapy with Imatinib: An Exception or a Rule? Clinical Aspects of Imantinib Therapy. Isoquinolinesulfonamide, a Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy. Discovery and Development of Iressa - The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. eBook Springer PDF, Springer, 30.03.2006, Springer, 2006<
Nr. 24485740. Gastos de envío:, Sofort per Download lieferbar, DE. (EUR 0.00)
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkab… Más…
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles. TOC:From the Contents.- Protein Kinase Inhibitors for the Treatment of Disease; the Promise and the Problems.- Part 1: General Aspects of PKs Inhibition.- New Design Strategies for Ligands that Target Protein Kinase Mediated Protein-Protein Interactions.- Part 2: Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones, a Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase -3. Pharmacological Potential of p38 MAPK Inhibitors. Inhibitors of PKA and Related Protein Kinases. Inhibitors of Protein Kinase CK2: Structural Aspects. Aminoglycoside Kinases and Antibiotic Resistance.- Part 3: Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets. Structure-Based Design of PTP Inhibitors. Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target. Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Part 4: Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression Using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus. Targeted Therapy with Imatinib: An Exception or a Rule? Clinical Aspects of Imantinib Therapy. Isoquinolinesulfonamide, a Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy. Discovery and Development of Iressa - The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. eBook Springer PDF, Springer, 30.03.2006, Springer, 2006<
Nr. 24485740. Gastos de envío:, Sofort per Download lieferbar, DE. (EUR 0.00)
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkab… Más…
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles. TOC:From the Contents.- Protein Kinase Inhibitors for the Treatment of Disease; the Promise and the Problems.- Part 1: General Aspects of PKs Inhibition.- New Design Strategies for Ligands that Target Protein Kinase Mediated Protein-Protein Interactions.- Part 2: Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones, a Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase -3. Pharmacological Potential of p38 MAPK Inhibitors. Inhibitors of PKA and Related Protein Kinases. Inhibitors of Protein Kinase CK2: Structural Aspects. Aminoglycoside Kinases and Antibiotic Resistance.- Part 3: Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets. Structure-Based Design of PTP Inhibitors. Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target. Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Part 4: Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression Using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus. Targeted Therapy with Imatinib: An Exception or a Rule? Clinical Aspects of Imantinib Therapy. Isoquinolinesulfonamide, a Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy. Discovery and Development of Iressa - The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. eBook Springer 30.03.2006, Springer, Springer<
Nr. 24485740. Gastos de envío:, Sofort per Download lieferbar, zzgl. Versandkosten. (EUR 16.85)
1Dado que algunas plataformas no nos comunican las condiciones de envío y éstas pueden depender del país de entrega, del precio de compra, del peso y tamaño del artículo, de una posible membresía a la plataforma, de una entrega directa por parte de la plataforma o a través de un tercero (Marketplace), etc., es posible que los gastos de envío indicados por eurolibro/terralibro no concuerden con los de la plataforma ofertante.
Detalles del libro - Inhibitors of Protein Kinases and Protein Phosphates
EAN (ISBN-13): 9783540266709 ISBN (ISBN-10): 3540266704 Año de publicación: 2006 Editorial: Springer Berlin 458 Páginas Idioma: eng/Englisch
Libro en la base de datos desde 2009-12-21T23:28:52-06:00 (Mexico City) Página de detalles modificada por última vez el 2023-02-11T05:18:16-06:00 (Mexico City) ISBN/EAN: 9783540266709
ISBN - escritura alterna: 3-540-26670-4, 978-3-540-26670-9 Mode alterno de escritura y términos de búsqueda relacionados: Autor del libro: born, pinna, lorenzo, cohen Título del libro: inhibitors protein, kina kina, handbook experimental pharmacology
Datos del la editorial
Autor: Lorenzo A. Pinna; Patricia T.W. Cohen Título: Handbook of Experimental Pharmacology; Inhibitors of Protein Kinases and Protein Phosphates Editorial: Springer; Springer Berlin 458 Páginas Año de publicación: 2006-03-30 Berlin; Heidelberg; DE Impreso en Idioma: Inglés 523,23 € (DE) 537,90 € (AT) 590,00 CHF (CH) Available X, 458 p.
EA; E107; eBook; Nonbooks, PBS / Medizin/Pharmazie; Pharmakologie; Verstehen; Anticancer drugs; Antidiabetes targets; Calcineurin-Inhibitor; Cell signalling; Glycogen; Immunosuppressants; Signal transduction therapy; B; Pharmacology/Toxicology; Oncology; Pathology; Medical Biochemistry; Pharmacology; Oncology; Pathology; Medical Biochemistry; Biomedical and Life Sciences; Onkologie; Pathologie; Medizinische Chemie, Pharmazeutische Chemie; BB
Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems.- General Aspects of PKs Inhibition.- New Design Strategies for Ligands That Target Protein Kinase-Mediated Protein-Protein Interactions.- Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones: A Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3.- Pharmacological Potential of p38 MAPK Inhibitors.- Inhibitors of PKA and Related Protein Kinases.- Inhibitors of Protein Kinase CK2: Structural Aspects.- Aminoglycoside Kinases and Antibiotic Resistance.- Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets.- Structure-Based Design of Protein Tyrosine Phosphatase Inhibitors.- Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target.- Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus.- Targeted Therapy with Imatinib: An Exception or a Rule?.- Clinical Aspects of Imatinib Therapy.- Isoquinolinesulfonamide: A Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy.- Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase.
Más, otros libros, que pueden ser muy parecidos a este:
